


Amended Claims

1. (Original) Compounds having the structure of Formula I



and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, or metabolites, wherein

Ar represents an aryl or a heteroaryl ring having 1-2 hetero atoms selected from the group consisting of oxygen, sulphur and nitrogen atoms, the aryl or heteroaryl rings may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (C₁-C₄), lower perhaloalkyl (C₁-C₄), cyano, hydroxy, nitro, halogen (e.g. F, Cl, Br, I), lower alkoxy (C₁-C₄), lower perhaloalkoxy (C₁-C₄), unsubstituted amino, N-lower alkylamino (C₁-C₄) or N-lower alkylamino carbonyl (C₁-C₄);

R₁ represents a hydrogen, hydroxy, hydroxymethyl, amino, alkoxy, carbamoyl or halogen (e.g. fluorine, chlorine, bromine and iodine);

R₂ represents hydrogen, alkyl, C₃-C₇ cycloalkyl ring, a C₃-C₇ cycloalkenyl ring, an aryl or a heteroaryl ring having 1-2 hetero atoms selected from the group consisting of oxygen, sulphur and nitrogen atoms, the aryl or a heteroaryl ring may be unsubstituted or substituted by one to three substituents independently selected from lower alkyl (C₁-C₄), cyano, hydroxy, nitro, lower alkoxycarbonyl, halogen, lower alkoxy (C₁-C₄), lower perhaloalkoxy (C₁-C₄), unsubstituted amino, N-lower alkylamino (C₁-C₄), N-lower alkyl amino carbonyl (C₁-C₄);

W represents (CH₂)_p, where p represents 0 to 1;

X represents an oxygen, sulphur, -NR or no atom, wherein R represents H or alkyl;

Y represents (CH₂)_q wherein q represents 0 to 1;

29 R₃, R₅ and R₆ are independently selected from H, lower alkyl, COOH, CONH₂,
30 NH₂, CH₂NH₂; and

31 R₄ represents hydrogen, C₁-C₁₅ saturated or unsaturated aliphatic hydrocarbon
32 (straight chain or branched) in which any 1 to 6 hydrogen atoms may be
33 substituted with the group independently selected from halogen, arylalkyl,
34 arylakenyl, heteroarylalkyl or heteroarylalkenyl, having 1-2 hetero atoms selected
35 from the group consisting of nitrogen, oxygen and sulphur atoms with an option
36 that any 1 to 3 hydrogen atoms on the ring in said arylalkyl, arylalkenyl,
37 heteroarylalkyl, heteroarylalkenyl group may be substituted with lower alkyl (C₁-
38 C₄), lower perhaloalkyl (C₁-C₄), cyano, hydroxy, nitro, lower alkoxy, carbonyl,
39 halogen, lower alkoxy (C₁-C₄), lower perhalo alkoxy (C₁-C₄), unsubstituted amino,
40 N-lower alkylamino (C₁-C₄), or N-lower alkylamino carbonyl (C₁-C₄).

1 2. (Original) A compound selected from the group consisting of
2 (1 α , 5 α)-[3-benzyl-3-azabicyclo[3.1.0]-hex-1-(methyl)-yl]-2-hydroxy-2,2-
3 diphenylcarboxylic ester (Compound No.1)
4 (1 α , 5 α)-[3-benzyl-3-azabicyclo[3.1.0]-hex-1-(methyl)-yl]-2-hydroxy-2-cyclohex
5 yl-2-phenylcarboxylic ester (Compound No.2)
6 (1 α , 5 α)-[3-benzyl-3-azabicyclo[3.1.0]-hex-1-(methyl)-yl]-2-hydroxy-2-
7 cyclopentyl-2-phenylcarboxylic ester (Compound No.3)
8 (1 α , 5 α)-[3-benzyl-3-azabicyclo[3.1.0]-hex-1-yl]-2-hydroxymethyl-2-
9 phenylacetamide (Compound No.4)
10 (1 α , 5 α)-[3-benzyl-3-azabicyclo [3.1.0]-hex-1-yl]-2-hydroxy-2,2-
11 diphenylacetamide (Compound No.5)
12 (1 α , 5 α)-[3-(2-methyl-2-pentenyl)-3-azabicyclo[3.1.0]-hex-1-(methyl)-yl]-2-
13 hydroxy-2-cyclohexyl-2-phenylcarboxylic ester (Compound No.6)
14 (1 α , 5 α)-[3-(3,4-methylenedioxyphenyl)ethyl-3-azabicyclo[3.1.0]-hex-1-(methyl)-
15 yl]-2-hydroxy-2-cyclohexyl-2-phenylcarboxylic ester (Compound No.7).

1 3. (Original) A pharmaceutical composition comprising a therapeutically effective
2 amount of a compound as defined in claim 1 or 2 optionally together with
3 pharmaceutically acceptable carriers, excipients or diluents.

1 4.- 17 (Canceled).